CapsulesCapsules
Schedule H (Prescription Required)Orthopedic & Joint CareCode: 2849

Polmacoxib 2 Mg Capsules

Generic Formulation:Polmacoxib 2 Mg Capsules
Pack Size:10's

MRP Under Process

Official PMBI MRP is being updated for catalog code 2849.

Locate Jan Aushadhi Kendra
Clinical InformationReport Error

Clinical Overview

Polmacoxib Capsules (2mg) is a first-in-class, tissue-specific dual COX-2 and carbonic anhydrase (CA) inhibitor. It binds with high affinity to carbonic anhydrase enzymes inside erythrocytes, which act as a physiological circulating reservoir, transporting polmacoxib specifically to inflamed arthritic joints where local acidic pH promotes drug dissociation into synovial tissue. This targeted delivery allows powerful articular COX-2 inhibition at ultra-low systemic doses (2 mg once daily), markedly minimizing cardiovascular and gastrointestinal toxicities. Indicated for the relief of signs and symptoms of osteoarthritis in adults.

Active Pharmaceutical Ingredients

AI-assistedClinical summary synthesized from pharmacopoeial references (CDSCO, WHO EML, IP/BP/USP). Not clinician-reviewed. Drug code 2849.Report inaccuracy

Usage Guidelines

Take orally 2 mg once daily after food with a glass of water. Swallow capsule whole.

General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.

Possible Side Effects

Common: Mild dyspepsia, nausea, headache, diarrhea, abdominal discomfort. Rare/Severe: Hypertension, peripheral edema, and cardiovascular thrombotic events.

*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.

Precautions & Warnings

Contraindicated in patients with known hypersensitivity to sulfonamides, active peptic ulcer disease, or severe cardiovascular disease. Ultra-low dose confers improved safety profile compared to conventional high-dose NSAIDs.

Schedule H (Prescription Required)

This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.

Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or analgesic treatment guidance. Always consult a registered physician or orthopedic specialist before taking pain relievers, anti-inflammatory medications, or anti-arthritic therapies.